K-numberK243709
Device nameNeuroEars-Anna™
ApplicantNeuroears, Inc.
Product codeGWN
Device classClass II
Decision dateAug 25, 2025
DecisionSubstantially Equivalent
Regulation882.1460
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

NeuroEars-Anna™ is software that analyzes eye movements using a head-mounted display with eye-tracking cameras to assist trained medical professionals in nystagmographic evaluation, diagnosis, and documentation of vestibular disorders. The system performs 13 vestibular tests including spontaneous nystagmus, gaze-evoked nystagmus, dix-hallpike, caloric, and smooth pursuit tests. It is intended for use in individuals aged 12 years and older by trained personnel such as audiologists, ENT surgeons, and doctors.

Technological characteristics

The subject device uses a commercially available head-mounted display (FOVE VR headset) with 2D/3D eye-tracking cameras running on a Windows PC platform, versus the predicate device which uses goggles with mounted cameras. Both devices perform identical vestibular tests and analyze eye movement data. The subject device was validated to meet ANSI S3.45 standards with eye-tracking accuracy within 1.0° error and minimum 60 Hz frame rate.

Test standards cited

ANSI S3.45-2009 (Reaffirmed April 16, 2024) for eye-tracking specifications in videonystagmography. Performance testing verified frame rate (120 Hz minimum), eye-tracking accuracy (horizontal and vertical error within 1.0°), and visual fixation point requirements (0.2–0.4 Hz movement within 20° horizontal field of view).

Substantial equivalence argument

NeuroEars-Anna™ has identical indications for use, intended user and patient populations, and vestibular test functionality as the predicate I-Portal device (K143607). Although the subject device uses a head-mounted VR display instead of traditional goggles, clinical testing demonstrated it provides equivalent eye-movement measurements, and performance testing confirmed it meets the same ANSI S3.45 technical standards. The minor hardware difference does not raise new safety or effectiveness concerns because both capture and analyze eye movement data identically for vestibular diagnostic purposes.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →